Western New England University (WNE) has received a $500,000 grant from the Healey-Driscoll Administration to establish a new interdisciplinary Master’s in Biopharmaceutical Technology program. This funding is part of a $13.1 million award from the Massachusetts Life Sciences Center (MLSC) aimed at advancing life sciences education across the state.

The new program integrates WNE’s expertise in pharmaceutical sciences and engineering, offering students a comprehensive education in biopharmaceuticals. Focusing on advanced therapeutic medicinal products (ATMPs), such as gene and cell therapies, this program aligns with federal initiatives to enhance biotech and biomanufacturing capabilities.

The degree will help address critical health areas like cancer and neurodegenerative diseases, enhancing students’ potential to transform patient care. The program targets students with a background in sciences, engineering, mathematics, or pharmacy.

The MLSC grant will support over 5,000 students statewide by expanding life sciences education and training programs, helping to meet the growing demand for skilled professionals in biotechnology and biopharmaceuticals.